This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vlotides, G. Articles by Melmed, S. Search for Related Content PubMed PubMed Citation Articles by Vlotides, G. Articles by Melmed, S.

Rat Prolactinoma Cell Growth Regulation by Epidermal Growth Factor Receptor Ligands

Department of Medicine, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles, California

Requests for reprints: Shlomo Melmed, Academic Affairs, Cedars-Sinai Medical Center, Room 2015, 8700 Beverly Boulevard, Los Angeles, CA 90048. Phone: 310-423-4691; Fax: 310-423-0119; E-mail: melmed{at}csmc.edu.

Key Words: Pituitary tumor • Prolactinoma • GH3 cells • PRL • EGFR

Epidermal growth factor (EGF) regulates pituitary development, hormone synthesis, and cell proliferation. Although ErbB receptor family members are expressed in pituitary tumors, the effects of EGF signaling on pituitary tumors are not known. Immunoprecipitation and Western blot confirmed EGF receptor (EGFR) and p185^c-neu protein expression in GH3 lacto-somatotroph but not in adrenocorticotropic hormone–secreting AtT20 pituitary tumor cells. EGF (5 nmol/L) selectively enhanced baseline (4-fold) and serum-induced (>6-fold) prolactin (PRL) mRNA levels, whereas gefitinib, an EGFR antagonist, suppressed serum-induced cell proliferation and Pttg1 expression, blocked PRL gene expression, and reversed EGF-mediated somatotroph-lactotroph phenotype switching. Downstream EGFR signaling by ERK, but not phosphoinositide-3-kinase or protein kinase C, mediated the gefitinib response. Tumors in athymic mice implanted s.c. with GH3 cells resulted in weight gain accompanied by increased serum PRL, growth hormone, and insulin growth factor 1. Gefitinib decreased tumor volumes and peripheral hormone levels by 30% and restored normal mouse body weight patterns. Mice treated with gefitinib exhibited decreased tumor tissue ERK1/2 phosphorylation and down-regulated tumor PRL and Pttg1 mRNA abundance. These results show that EGFR inhibition controls tumor growth and PRL secretion in experimental lacto-somatotroph tumors. EGFR inhibitors could therefore be useful for the control of PRL secretion and tumor load in prolactinomas resistant to dopaminergic treatment, or for those prolactinomas undergoing rare malignant transformation. [Cancer Res 2008;68(15):6377–86]

This article has been cited by other articles:

				G. Vlotides, O. Cooper, Y.-H. Chen, S.-G. Ren, Y. Greenman, and S. Melmed Heregulin Regulates Prolactinoma Gene Expression Cancer Res., May 15, 2009; 69(10): 4209 - 4216. [Abstract] [Full Text] [PDF]